StreetInsider.com News Articles

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA company specializing in the genomics of cancer and rare genetic diseases, which performs interpretable genomic analyses for academic and private laboratories,

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen: Sales of €2.5 Million in the First Half of 2025 and Cash Position of €2.1 Million

Wed, 02 Jul 2025 01:30:00 -0400

Sequencing activities at Évry down 31%
Decrease in activities on the P2M microbiology platform operated on the Institut Pasteur site
Free cash position of €2.1m at June 30, 2025, after a consumption of €0.9m in the first half. The cash situation at this rate of consumption may not allow the company to continue its activities without new financing beyond the first quarter of 2026

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:

IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.

Bernard

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard

IntegraGen: 2024 Annual Results

Tue, 29 Apr 2025 12:00:00 -0400

7% increase in genomic services provided in Evry in 2024 and stability in activities operated for the Institut Pasteur

Operating costs cut by 24% and net loss limited to €256k

Accelerated development of activities for the pharmaceutical industry following CAP accreditation and CLIA certification

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its yearly audited annual results 2025, following approval by the Board of Directors on April 10th, 2025.
Bernard

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Revenues of €8.5m, Down 27% Compared With 2023 (+5% Excluding SeqOIA), and Cash Position of €1.9m

Wed, 15 Jan 2025 12:44:00 -0400

- Revenues down 27% due to the discontinuation of services for the SeqOIA platform. Adjusted for this base effect, growth stood at 5% over the period.

- Cash position of 1,895 k€ at December 31, 2024.

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announces its unaudited revenue for the year 2024.
Unaudited revenue recognized over the year 2024 amounts to €8 489k, down 27% compared to that of 2023. This decline is

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts

IntegraGen: 2024 Half-Year Results - Sales up 6% on a Like-for-Like Basis (Excluding SeqOIA) and Profitability Maintained

Thu, 17 Oct 2024 12:29:00 -0400

Revenue growth for the Évry laboratory activities

Restructuring and cost reduction plan implemented after cessation of services to SeqOIA in February

Overall profitability remained stable

EVRY, France--(BUSINESS WIRE)-- Regulatory News:
IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA Group company specializing in cancer and rare genetic disease genomics, and providing genomic analyses for both academic and private clients, today announced its unaudited results for the first half of 2024, following approval by the Board of Directors on October 15, 2024
Bernard Courtieu, Chief Executive Officer of IntegraGen, comments: “The first half of 2024 was marked by intensified commercial efforts